EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluation of Drug‐Drug Interactions of Ensitrelvir, a SARS‐CoV‐2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies

Ryosuke Shimizu, Takanobu Matsuzaki, Ryoko Oka, Takuhiro Sonoyama, Takahiro Fukuhara, Aya Kuwata, Yumiko Matsuo, Ryuji Kubota

The Journal of Clinical Pharmacology · 2023

DOI: 10.1002/jcph.2247 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2023. Verfasst von Ryosuke Shimizu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Pharmacokinetics, Shionogi & Co., Ltd., Osaka, Japan. Hauptthemen laut MEDLINE: COVID-19, Organic Anion Transporters, Metformin. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug‐drug interaction potentials of ensitrelvir, a novel oral inhibitor of 3C‐like protease of severe acute respiratory syndrome coronavirus 2, for drug transporters were evaluated by in vitro and clinical studies. The target drug transporters assessed were P‐glycoprotein (P‐gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic anion transporter (OAT) 1, OAT3, organic cation transporter (OCT) 1, OCT2, and multidrug and toxin extrusion 1 and 2K. In vitro study revealed that ensitrelvir is a substrate for P‐gp and BCRP and inhibits P‐gp, BCRP, OATP1B1, OATP1B3, OCT1, and OAT3. Based on these results, a clinical drug‐drug interaction study to evaluate the effect of ensitrelvir on the pharmacokinetics of P‐gp, BCRP, OATP1B1, OATP1B3, and OCT1 substrates was conducted with a cocktail approach using digoxin (P‐gp substrate), rosuvastatin (BCRP, OATP1B1, and OATP1B3 substrate), and metformin (OCT1 substrate). The cocktail was administered first, and after the washout period, the cocktail was coadministered with 500 mg of ensitrelvir. No treatment‐emergent adverse events were observed. Pharmacokinetic analyses demonstrated that the ratios (90% confidence intervals) of “cocktail with ensitrelvir” to “cocktail without ensitrelvir” for maximum plasma concentration and area under the plasma concentration–time curve were, respectively, 2.17 (1.72‐2.73) and 1.31 (1.13‐1.52) for digoxin, 1.97 (1.73‐2.25) and 1.65 (1.47‐1.84) for rosuvastatin, and 1.03 (0.91‐1.16) and 1.02 (0.94‐1.11) for metformin. The results indicate that the exposure levels of digoxin and rosuvastatin increased when coadministered with ensitrelvir, but those of metformin were not changed. In conclusion, ensitrelvir has an impact on the exposure levels of P‐gp, BCRP, OATP1B1, and OATP1B3 substrates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Organic Anion TransportersMetforminHumansATP Binding Cassette Transporter, Subfamily G, Member 2SARS-CoV-2Rosuvastatin CalciumProtease InhibitorsNeoplasm ProteinsMembrane Transport ProteinsDrug InteractionsATP Binding Cassette Transporter, Subfamily B, Member 1DigoxinEnzyme InhibitorsOrganic Cation Transporter 1Biological TransportSolute Carrier Organic Anion Transporter Family Member 1B3IndazolesTriazinesTriazoles

Stichwörter der Autor:innen

cocktaildrug-drug interactionsensitrelvirtransporters

Substanzen

ATP Binding Cassette Transporter, Subfamily G, Member 2Rosuvastatin CalciumProtease InhibitorsNeoplasm ProteinsMembrane Transport ProteinsATP Binding Cassette Transporter, Subfamily B, Member 1Organic Anion TransportersDigoxinEnzyme InhibitorsOrganic Cation Transporter 1

Autor:innen und Institutionen

  • Clinical Pharmacology & Pharmacokinetics, Shionogi & Co., Ltd., Osaka, Japan.
  • Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd., Osaka, Japan.
  • Medical Science Department, Shionogi & Co., Ltd., Osaka, Japan.
  • Clinical Research Department, Shionogi & Co., Ltd., Osaka, Japan.
  • Present Address: Product Development & Clinical Pharmacology, IDEC Inc., Tokyo, Japan.

Zitieren

APA

Shimizu, R., Matsuzaki, T., Oka, R., Sonoyama, T., Fukuhara, T., Kuwata, A., Matsuo, Y., & Kubota, R. (2023). Evaluation of Drug‐Drug Interactions of Ensitrelvir, a SARS‐CoV‐2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2247

Vancouver

Shimizu R, Matsuzaki T, Oka R, Sonoyama T, Fukuhara T, Kuwata A, et al. Evaluation of Drug‐Drug Interactions of Ensitrelvir, a SARS‐CoV‐2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies. The Journal of Clinical Pharmacology. 2023. doi:10.1002/jcph.2247

BibTeX
@article{Shimizu2023,
  author = {Shimizu, Ryosuke and Matsuzaki, Takanobu and Oka, Ryoko and Sonoyama, Takuhiro and Fukuhara, Takahiro and Kuwata, Aya and Matsuo, Yumiko and Kubota, Ryuji},
  title = {Evaluation of Drug‐Drug Interactions of Ensitrelvir, a SARS‐CoV‐2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies},
  journal = {The Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1002/jcph.2247}
}
Kostenlos starten →